Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …

Background The survival of patients with diffuse large-B-cell lymphoma after chemotherapy
is influenced by molecular features of the tumors. We used the gene-expression profiles of …

The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains
the least curable form of this malignancy despite recent advances in therapy 1 . Constitutive …

We herein present an overview of the upcoming 5 th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important
subgroups with germinal center B-cell–like (GCB), activated B-cell–like (ABC), and type 3 gene …

MicroRNAs comprise a broad class of small non-coding RNAs that control expression of
complementary target messenger RNAs 1 , 2 . Dysregulation of microRNAs by several …

A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying
immunoglobulin genes in human lymphomas 1 , 2 and by engineering mouse models 3 , …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell…

Background Patients with follicular lymphoma may survive for periods of less than 1 year to
more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy …

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy
of mature B cells with a characteristic clinical presentation but a variable clinical course. …